Target Price | $78.67 |
Price | $53.35 |
Potential |
47.45%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target ANI Pharmaceuticals, Inc. 2025 .
The average ANI Pharmaceuticals, Inc. target price is $78.67.
This is
47.45%
register free of charge
$94.00
76.19%
register free of charge
$62.00
16.21%
register free of charge
|
|
A rating was issued by 6 analysts: 5 Analysts recommend ANI Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the ANI Pharmaceuticals, Inc. stock has an average upside potential 2025 of
47.45%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 486.82 | 598.90 |
53.87% | 23.02% | |
EBITDA Margin | 22.46% | 25.10% |
127.43% | 11.77% | |
Net Margin | 4.07% | -0.64% |
120.03% | 115.72% |
6 Analysts have issued a sales forecast ANI Pharmaceuticals, Inc. 2024 . The average ANI Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an ANI Pharmaceuticals, Inc. EBITDA forecast 2024. The average ANI Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 ANI Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average ANI Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 0.94 | -0.18 |
130.82% | 119.15% | |
P/E | negative | |
EV/Sales | 2.70 |
4 Analysts have issued a ANI Pharmaceuticals, Inc. forecast for earnings per share. The average ANI Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the ANI Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
ANI Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.